Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D VanScoy

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|November 9, 2011
Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic systemArnold Louie, Brian D Vanscoy, Henry S Heine, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an <i>In Vitro</i> Infection ModelBrian D VanScoy, David Tenero, Simon Turner, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2021
Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber <i>In Vitro</i> Infection Model SystemsBrian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber <i>In Vitro</i> Infection ModelBrian D VanScoy, Nicole E Scangarella-Oman, Steven Fikes, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2018
Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection ModelM Montero, Brian D VanScoy, Carla López-Causapé, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2014
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection modelBrian D VanScoy, Rodrigo E Mendes, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2023
Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric ApproachesA J Lepak, M Trang, J P Hammel, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2019
Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen EffectPaul G Ambrose, Brian D VanScoy, Brian M Luna, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation SolutionSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Antimicrobial Agents and Chemotherapy|January 21, 2016
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection ModelAnthony M Nicasio, Brian D VanScoy, Rodrigo E Mendes, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|November 9, 2011
Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic systemArnold Louie, Brian D Vanscoy, Henry S Heine, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an <i>In Vitro</i> Infection ModelBrian D VanScoy, David Tenero, Simon Turner, et al.
Antimicrobial Agents and Chemotherapy|September 20, 2021
Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber <i>In Vitro</i> Infection Model SystemsBrian D VanScoy, Elizabeth A Lakota, Haley Conde, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber <i>In Vitro</i> Infection ModelBrian D VanScoy, Nicole E Scangarella-Oman, Steven Fikes, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2018
Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection ModelM Montero, Brian D VanScoy, Carla López-Causapé, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2014
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection modelBrian D VanScoy, Rodrigo E Mendes, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2023
Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric ApproachesA J Lepak, M Trang, J P Hammel, et al.
Antimicrobial Agents and Chemotherapy|February 21, 2019
Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen EffectPaul G Ambrose, Brian D VanScoy, Brian M Luna, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2020
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation SolutionSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Antimicrobial Agents and Chemotherapy|January 21, 2016
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection ModelAnthony M Nicasio, Brian D VanScoy, Rodrigo E Mendes, et al.
Pageof 3